Newton, Mass., September 12, 2006.
NeuroHealing Pharmaceuticals Inc., a private company developing innovative therapeutic products for neuro- rehabilitation, today announced that its CEO Neal M. Farber, Ph.D., has accepted invitations to speak at three upcoming investor conferences. Dr. Farber will speak at the Dow Jones VentureWire Health Care Innovations conference scheduled for September 12-13 at the Sofitel San Francisco Bay Hotel in Redwood City, California. Dr. Farber will also speak during the Biotech Life Sciences Global Venture Congress 2006 conference scheduled for September 14-16 in New York City and at the Life Sciences Venture Summit 2006 scheduled for October 25 in New York City.
The Dow Jones VentureWire Health Care Innovations Conference (http://www.healthcaredowjones.com) attracts leading entrepreneurs corporate investors venture capitalists and business development executives who are building startup companies in the health care sector. The conferences agenda features key executives investors and analysts and offers investment and partnership opportunities to participants.
The Biotech Life Sciences Global Venture Congress conference (http://www.biosaeclub.com/Bio2006) is designed to explore the frontiers of biotech, life sciences address the venture capital landscape identify current trends in innovation learn scientific discoveries and discover cutting-edge biotech and life sciences companies.
The 2006 Life Sciences Venture Summit (www.youngstartup.com/lifesciences) is a premier bioscience industry gathering connecting senior executives of early stage biotech pharmaceutical healthcare medical device and diagnostic companies with venture capitalists angel investors corporate VCs and professional service firms.
“The invitation to speak at each of these top investor conferences affirms NeuroHealing’s position as one of the most innovative neuroscience companies in the healthcare sector,” said Neal Farber, NeuroHealing’s CEO. “I very much look forward to contributing to such prestigious events and introducing the investment community to NeuroHealing’s clinical-stage product story.”
NeuroHealing Pharmaceuticals Inc. (www.NeuroHealing.com) is a clinical stage company developing therapies to improve the neuro-rehabilitation process and functional outcome for patients who have suffered debilitating injuries to the central nervous system. Clinical stage programs include NH001 (phase II) a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative or minimally consciousness state NH004 (phase II) an anticholinergic agent in a convenient intra- orally muco-adhesive dissolving film to help treat motor neuron patients who suffer from sialorrhea (drooling) and NH02D a novel mechanism compound to accelerate the rehabilitation outcomes of stroke patients who remain with chronic motor and cognitive disabilities.